This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Plantation, FL

Detroit, MI

Neuro-Oncology Department

Pediatric Endocrinology Department

Las Vegas, NV

Newport Beach, CA

Beverly Hills, CA

Los Angeles, CA

Mirati Therapeutics

Study 849-010 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

The purpose of this study is to investigate treatment with nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer of the colon or rectum that has spread.

An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread

Bristol-Myers Squibb (BMS)

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon or rectal cancer.

S0820, Adenoma and Second Primary Prevention Trial

Preventive Medicine

Wright-Patterson Medical Center

Cancer Research Department

Oncology Department

UMC Hospital, Clinical Trials Office

Department of Research and Evaluation

SWOG Cancer Research Network

This is a multicenter, open-label, dose-escalation, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, pharmacokinetic (PK), pharmacodynamics, and immunogenicity of durvalumab (MEDI4736) in combination with monalizumab (IPH2201) in adult participants with selected advanced solid tumors and the combination of durvalumab and monalizumab (IPH2201) standard of care systemic therapy with or without biological agent and monalizumab (IPH2201) with biological agent administered to participants with recurrent or metastatic colorectal cancer (CRC).

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

MedImmune

Find clinical trials for Colon Cancer in Birmingham, AL

Related conditions:

Colon Cancer trials near Birmingham, AL, USA:

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread (CheckMate 9N9)

S0820, Adenoma and Second Primary Prevention Trial (PACES)

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

Find clinical trials for Colon Cancer in .css-epvm6{white-space:nowrap;}Birmingham, AL

Related conditions:

Colon Cancer trials near Birmingham, AL, USA:

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread (CheckMate 9N9)

S0820, Adenoma and Second Primary Prevention Trial (PACES)

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

Find clinical trials for Colon Cancer in Birmingham, AL